Circulating Free Hemoglobin and Microcirculation After Administration of Paracetamol in Febrile Septic Patient
NCT ID: NCT02750163
Last Updated: 2019-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2017-07-05
2019-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Paracetamol Toxicity in Septic Patients
NCT01182974
Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis
NCT01739361
Heamodynamic Effects of Paracetamol in Septic Shock Patients
NCT06076980
Platelet Reactivity in Septic Shock
NCT03716310
Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
NCT04291508
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In all these conditions, high levels of free hemoglobin were associated with poor outcome and with serious complications such as acute renal failure and myocardial infarction.
In the animal model of sepsis, increased values of plasma free hemoglobin has been related to increased mortality, especially if a concomitant lack of haptoglobin and hemopexin coexists.
It is likely that the release of free hemoglobin in the blood of septic patient is attributable to changes in the membrane of red blood cells.
These changes have been recognized in humans as a source of damage of the vascular endothelium and consumption of free radical scavenger systems.
It has been hypothesized that the extracellular hemoglobin, when the protective mechanism have been saturated, causes - trough reaction with NO - the formation of nitrate and lipids peroxidation and boosts the immune response mediated by the monocyte -macrophage system.
It is also liable for a condition of endothelial dysfunction and NO resistance that could impair the microcirculation.
Our previous work showed that higher levels of free hemoglobin resulted in a significant reduction in the density of the microcirculation in septic patients undergoing blood transfusions.
On animal model Paracetamol (or acetaminophen), drug commonly used for its analgesic and antipyretic effects, demonstrated strong efficacy in preventing oxidative damage and protection of renal damage in the context of increased levels of plasma free hemoglobin (as in Rhabdomyolysis and myoglobulinemie).
This effect is attributed to the ability of the Paracetamol to cross react with either nitric oxide synthase (NOS) by increasing the synthesis of NO, and with cyclooxygenase (COX), by inhibiting the synthesis of prostaglandin I2 (PGI2-antiplatelet and vasodilator effect) without interfering with the production of Thromboxane A2 (TXA2-powerful vasoconstrictor and pro-thrombogenic) causing an imbalance of endovascular homeostasis.
The increased oxidative stress produced by sepsis is also responsible of glycocalix damage, the thin layer that lines the surface of endothelium in contact with the blood and increased the free hemoglobin.
ROS are also responsible to up-regulation of Programmed Death-1 related molecules (PD-1/PD-L1) that render T cells susceptible to inhibitory modulation, inability to proliferate and reduced capacity to clear bacteria, inducing "immunosuppression" and more difficult recovery from septic shock. PD-1/PD-L1 system has been recently studied as potential predictor of mortality and active player in resolution of sepsis-induced Acute Lung Injury.
Finally, a recent study on septic patient showed an increased mortality in people with elevated values of free hemoglobin versus patients without this increase, and the efficacy of of Paracetamol to reduce the concentration of F2- isoprostane (marker of oxidative stress), associated with lower risk of death.
This effect was lost in the cohort of septic patients without free hemoglobin registered.
Aim of this study is to evaluate the effect of paracetamol administration on the microcirculation, on the plasmatic levels of free hemoglobin/oxidative stress markers and on the expression of PD1/Pd-L1, in pyrexial septic patient. Paracetamol is given only on the basis of a clinical indication, not because of the study and in our institution paracetamol is the drug of choice to treat fever.
When there are inclusion criteria (febrile septic patient) and no exclusion criteria, and patient is going to receive paracetamol, informed consent will be taken. When the neurological conditions do not permit, relatives will be informed and the patients will still included in the protocol. The informed consent will be taken when the patient clinical condition permits it.
Before the administration of the drug, at the end of infusion and after 30 minutes after infusion, the main parameters of the sublingual microcirculation will be monitored, using the the incident dark field imaging technique (IDF), including an assessment of glycocalyx, Near InfraRed (NIRS) parameters with the vascular occlusion test (VOT), vital signs and the dosage of any infusion of vasoactive drug.
Demographic and clinical records will be collected at T0 and T1. Acute lung injury will be investigated through gas analytical and laboratory data at the same timepoints.
Arterial blood samples will be collected at T0 and 2 hours after the infusion of Acetaminophen (that will represent T2). Blood will be immediately centrifuged and plasma and serum samples will be stored at -70°C for subsequent analysis. We will measure: fHb levels, markers of oxidative damage (F2-isoprastane and F2-isoflurane), of endothelial cell injury (endothelin-1) and glycocalyx damage (sindecan-1, heparasulfate), PD-1/PD-L1.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
paracetamol
Paracetamol will be given to febrile septic patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnancy
* hemodialysis
* hemolysis of the blood sample
* use of Paracetamol in the previous 12 hours
* conditions that do not allow the possibility of getting a monitoring of sublingual microcirculation (maxillofacial trauma, serious inability to jaw, copious blood loss or secretions from the mouth)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Università Politecnica delle Marche
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abele Donati, MD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AOU Ospedali Riuniti Ancona - Università Politecnica delle Marche
Ancona, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Scorcella C, Domizi R, Amoroso S, Carsetti A, Casarotta E, Castaldo P, D'angelo C, Damiani E, Gasparri F, Donati A, Adrario E. Pharmacogenetics in critical care: association between CYP3A5 rs776746 A/G genotype and acetaminophen response in sepsis and septic shock. BMC Anesthesiol. 2023 Feb 16;23(1):55. doi: 10.1186/s12871-023-02018-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FreeHb
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.